Immutep Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.73
- Today's High:
- $1.89
- Open Price:
- $1.76
- 52W Low:
- $1.47
- 52W High:
- $3.45
- Prev. Close:
- $1.76
- Volume:
- 141200
Company Statistics
- Market Cap.:
- $164.05 million
- Book Value:
- 0.87
- Revenue TTM:
- $4.44 million
- Operating Margin TTM:
- -862.76%
- Gross Profit TTM:
- $-26627215
- Profit Margin:
- 0%
- Return on Assets TTM:
- -23.21%
- Return on Equity TTM:
- -39.41%
Company Profile
Immutep Ltd ADR had its IPO on 2012-04-17 under the ticker symbol IMMP.
The company operates in the Healthcare sector and Biotechnology industry. Immutep Ltd ADR has a staff strength of 0 employees.
Stock update
Shares of Immutep Ltd ADR opened at $1.76 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.73 - $1.89, and closed at $1.79.
This is a +1.7% increase from the previous day's closing price.
A total volume of 141,200 shares were traded at the close of the day’s session.
In the last one week, shares of Immutep Ltd ADR have increased by 0%.
Immutep Ltd ADR's Key Ratios
Immutep Ltd ADR has a market cap of $164.05 million, indicating a price to book ratio of 2.7687 and a price to sales ratio of 36.6612.
In the last 12-months Immutep Ltd ADR’s revenue was $4.44 million with a gross profit of $-26627215 and an EBITDA of $-37424136. The EBITDA ratio measures Immutep Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Immutep Ltd ADR’s operating margin was -862.76% while its return on assets stood at -23.21% with a return of equity of -39.41%.
In Q2, Immutep Ltd ADR’s quarterly earnings growth was a positive 0% while revenue growth was a negative 11.5%.
Immutep Ltd ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immutep Ltd ADR’s profitability.
Immutep Ltd ADR stock is trading at a EV to sales ratio of 577.3628 and a EV to EBITDA ratio of -3.2728. Its price to sales ratio in the trailing 12-months stood at 36.6612.
Immutep Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $86.01 million
- Total Liabilities
- $8.38 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $33000
- Dividend Payout Ratio
- 0%
Immutep Ltd ADR ended 2023 with $86.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $86.01 million while shareholder equity stood at $76.69 million.
Immutep Ltd ADR ended 2023 with $0 in deferred long-term liabilities, $8.38 million in other current liabilities, 370334456.00 in common stock, $-320657434.00 in retained earnings and $109962.00 in goodwill. Its cash balance stood at $68.38 million and cash and short-term investments were $68.38 million. The company’s total short-term debt was $136,756 while long-term debt stood at $780803.00.
Immutep Ltd ADR’s total current assets stands at $75.22 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.00 million compared to accounts payable of $7.86 million and inventory worth $0.
In 2023, Immutep Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $33000.
Comparatively, Immutep Ltd ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.79
- 52-Week High
- $3.45
- 52-Week Low
- $1.47
- Analyst Target Price
- $8.15
Immutep Ltd ADR stock is currently trading at $1.79 per share. It touched a 52-week high of $3.45 and a 52-week low of $3.45. Analysts tracking the stock have a 12-month average target price of $8.15.
Its 50-day moving average was $1.86 and 200-day moving average was $2.01 The short ratio stood at 17.82 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 600% are held by institutions.
Frequently Asked Questions About Immutep Ltd ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.